| Name | N-{2-[(5-Fluoro-2-{[2-methoxy-4-(4-morpholinyl)phenyl]amino}-4-pyrimidinyl)amino]phenyl}methanesulfonamide |
|---|---|
| Synonyms |
N-[2-[[5-Fluoro-2-[[2-Methoxy-4-(4-Morpholinyl)phenyl]amino]-4-pyriMidinyl]amino]phenyl]-MethanesulfonaMide hydrochloride
CZC-25146 hydrochloride CZC-25146.HCL;N-[2-[[5-FLUORO-2-[[2-METHOXY-4-(4-MORPHOLINYL)PHENYL]AMINO]-4-PYRIMIDINYL]AMINO]PHENYL]-METHANESULFONAMIDE HYDROCHLORIDE CZC-25146 hydrochloride >= (HPLC) CZC-25146 (hydrochloride) CZC-25146.HCl CZC-25146; CZC 25146; CZC25146;CZC25146 HYDROCHLORIDE;CZC 25146 HYDROCHLORIDE CZC-25146 hydrochL Leucine-rich reat kinase 2,CZC25146,neurons,RK2 G2019S,CZC 25146,Inhibitor,liver diseases,inflammatory,Pkinson's disease,RK2,inhibit,CZC-25146,CZC 25146 hydrochloride,CZC25146 hydrochloride |
| Description | CZC-25146 Hcl is a potent, selective and metabolically stable LRRK2 inhibitor with IC50 of 4.76 nM/6.87 nM for wild type LRRK2 and G2019S LRRK2 respectively.IC50 value: 4.76 nM/6.87 nM(wild type/G2019S LRRK2) [1]Target: LRRK2 CZC-25146displayed a very clean profile, it inhibited only five kinases(PLK4, GAK, TNK1, CAMKK2 and PIP4K2C) with high potency, none of which have been classified as predictors of genotoxicity or hematopoietic toxicity. CZC-25146 neither caused cytotoxicity in human cortical neurons at concentrations below 5μM over a seven-day treatment in culture nor did it block neuronal development in vitro. CZC-25146 possesses favorable pharmacokinetic properties, such as a volume of distribution of 5.4 L/kg and a clearance of 2.3 L/hr/kg that render it suitable for in-vivo studies. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 697.4±65.0 °C at 760 mmHg |
| Molecular Formula | C22H26ClFN6O4S |
| Molecular Weight | 525.00 |
| Flash Point | 375.5±34.3 °C |
| LogP | 1.50 |
| Vapour Pressure | 0.0±2.2 mmHg at 25°C |
| Index of Refraction | 1.655 |
| Storage condition | 2-8℃ |
| Symbol |
GHS06 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H301-H319 |
| Precautionary Statements | P301 + P310-P305 + P351 + P338 |
| RIDADR | UN 2811 6.1 / PGIII |